Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.80 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 0.80 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 0.80 |
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.80 |
| ▸ | FAP | Q12884 | 10/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5713152 | 1.00 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7298604 | 1.00 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27452954 | 1.00 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2195630 | 1.00 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5713150 | 1.00 | DPP4 (0.80) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL8501824 | 0.96 | DPP4 (0.74) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2183274 | 0.91 | DPP4 (0.67) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10792312 | 0.89 | DPP4 (0.67) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6453066 | 0.89 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7298573 | 0.87 | DPP4 (0.62) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4713369-A | Oligopeptidylargininol derivatives and their homologs, a process for their preparation, their use and agents containing them | BEHRINGWERKE AKTIENGELLSCHAFT (DE) | 1987-12-15 | — | — | US | claimed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| EP-0724446-A4 | ELECTROPHILIC PEPTIDE ANALOGS AS INHIBITORS OF TRYPSIN-LIKE ENZYMES | DU PONT MERCK PHARMA (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0724446-A1 | ELECTROPHILIC PEPTIDE ANALOGS AS INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995012408-A1 | PLASMIN-INDEPENDENT FIBRINOLYSIS | BRIGHAM & WOMEN'S HOSPITAL (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995009634-A1 | ELECTROPHILIC PEPTIDE ANALOGS AS INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | DPP4 525/4885DPP8 644/4885DPP9 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.